The Endless Sources of Hepatocellular Carcinoma Heterogeneity

Abstract

Hepatocellular carcinoma (HCC) represents a global health problem. The incidence keeps increasing and current therapeutic options confer limited benefits to the patients. Tumor heterogeneity plays a central role in this context, limiting the availability of predictive biomarkers and complicating the criteria used to choose the most suitable therapeutic option. HCC heterogeneity occurs at different levels: within the population (inter-patient heterogeneity) and within tumors from the same patient (intra-patient and intra-tumor heterogeneity). Experts in the field have made many efforts to classify the patients based on clinicopathological characteristics and molecular signatures; however, there is still much work ahead to be able to integrate the extra-tumor heterogeneity that emerges from the complexity of the tumor microenvironment, which plays a critical role in the pathogenesis of the disease and therapy responses. In this review, we summarize tumor intrinsic and extrinsic sources of heterogeneity of the most common etiologies of HCC and summarize the most recent discoveries regarding the evolutionary trajectory of liver cancer cells and the influence of tumor-extrinsic factors such as the microbiome and the host immune system. We further highlight the potential of novel high-throughput methodologies to contribute to a better understanding of this devastating disease and to the improvement of the clinical management of patients.

High-Mobility Group AT-Hook 1 Served as a Prognosis Biomarker and Associated with Immune Infiltrate in Hepatocellular Carcinoma

“… 12–15 Unfortunately, due to the complexity of immunotherapy and the genetic heterogeneity, this method took effect only for partial patients. 16 Emerging evidence demonstrated that the change of tumor-induced immune infiltrate cells was a momentous mechanism that carcinomas develop to evade immune surveillance. Meanwhile, tumor immune infiltration carries a clinicopathological significance in predicting prognosis and therapeutic efficacy.…”

Biochemical Mechanisms of Sirtuin-Directed Protein Acylation in Hepatic Pathologies of Mitochondrial Dysfunction

“…The etiology of hepatocellular carcinoma (HCC) is highly diverse and includes factors such as Hepatitis B and C, exposure to environmental toxicants, NAFLD, MetS, cigarette smoking, and ALD [173]. This heterogeneity makes treating HCC a significant challenge, leading to over 800,000 deaths worldwide each year [173]. The prognosis for HCC patients is poor (five-year survival rate less than 20%) and its diagnosis is rising in the United States [174][175][176].…”

VDAC Modulation of Cancer Metabolism: Advances and Therapeutic Challenges

“…Similar to muscle cells, most cancer cells are metabolically flexible. The different quantitative contributions of mitochondria to cellular bioenergetics, together with genomic instability and differences in the microenvironment, are important determinants of tumor heterogeneity (Kuipers et al, 2017;Barcena-Varela and Lujambio, 2021;Wei et al, 2021). Tumor metabolic heterogeneity is increasingly recognized as a factor causing failures in cancer treatment (Gentric et al, 2017;Kim and DeBerardinis, 2019).…”